AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31994303 — intervention group
Group type: EXPERIMENTAL
Intervention: 270 mg ferrous sulphate every other day (total elemental iron dose: 80 mg/every other day)
Number of subjects: 0
Study 31151337 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal Endoscopic Lumbar Discectomy (TELD)
Number of subjects: 298
Study 31151337 — intervention group
Group type: COMPARATOR
Intervention: Open Lumbar Microdiscectomy
Number of subjects: 298
Study 28183552 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 46
Study 28183552 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 46
Study 26002204 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility and balance exercises for 6 weeks
Number of subjects: 57
Study 26002204 — intervention group
Group type: COMPARATOR
Intervention: Flexibility program (control group)
Number of subjects: 57
Study 23314603 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg orally daily for 3 days
Number of subjects: 276
Study 23314603 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide 10 mg orally TID for 3 days
Number of subjects: 276
Study 21884372 — intervention group
Group type: EXPERIMENTAL
Intervention: Odor of breast milk during gavage feeding
Number of subjects: 80
Study 19019338 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivated group (training protocol, no reading glasses for 3 months, cycloplegic eye drops for 10 days)
Number of subjects: 40
Study 19019338 — intervention group
Group type: COMPARATOR
Intervention: Control group (no special training protocol)
Number of subjects: 40
Study 17595658 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine/carboplatin (VC)
Number of subjects: 432
Study 17595658 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine/carboplatin (GC)
Number of subjects: 432
Study 15179092 — intervention group
Group type: EXPERIMENTAL
Intervention: AH covered with ADMA
Number of subjects: 15
Study 15179092 — intervention group
Group type: EXPERIMENTAL
Intervention: ABB covered with ADMA
Number of subjects: 15
Study 15179092 — intervention group
Group type: EXPERIMENTAL
Intervention: AH covered with ePTFE
Number of subjects: 15
Study 15179092 — intervention group
Group type: EXPERIMENTAL
Intervention: ABB covered with ePTFE
Number of subjects: 15
Study 15179092 — intervention group
Group type: EXPERIMENTAL
Intervention: ADMA-covered sites
Number of subjects: 15
Study 15179092 — intervention group
Group type: EXPERIMENTAL
Intervention: ePTFE-covered sites
Number of subjects: 15
Study 11566255 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin and Niacin (S-N) therapy
Number of subjects: 61
Study 11566255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9502662 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive tocolysis with intravenous magnesium sulfate
Number of subjects: 145
Study 9502662 — intervention group
Group type: COMPARATOR
Intervention: No tocolysis
Number of subjects: 145
Study 30998533 — intervention group
Group type: EXPERIMENTAL
Intervention: PRBC+plasma
Number of subjects: 407
Study 30998533 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma
Number of subjects: 407
Study 30998533 — intervention group
Group type: EXPERIMENTAL
Intervention: PRBC
Number of subjects: 407
Study 30998533 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid only
Number of subjects: 407
Study 30998533 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid volume
Number of subjects: 407
Study 29882170 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic repair (LG)
Number of subjects: 193
Study 29882170 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid repair (HG)
Number of subjects: 193
Study 28893843 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography (CAG) <12 hours
Number of subjects: 4071
Study 28893843 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography (CAG) 12-24 hours
Number of subjects: 4071
Study 28893843 — intervention group
Group type: COMPARATOR
Intervention: Coronary angiography (CAG) ≥24 hours
Number of subjects: 4071
Study 25721702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged exercise group (n=6)
Number of subjects: 12
Study 25721702 — intervention group
Group type: EXPERIMENTAL
Intervention: Young exercise group (n=6)
Number of subjects: 12
Study 25721702 — intervention group
Group type: COMPARATOR
Intervention: Aged control group (n=5)
Number of subjects: 12
Study 25721702 — intervention group
Group type: COMPARATOR
Intervention: Young control group (n=6)
Number of subjects: 12
Study 23229426 — intervention group
Group type: EXPERIMENTAL
Intervention: Autotransfusion system for washed shed blood (WSB) used for 6 hours (intraoperatively and postoperatively)
Number of subjects: 151
Study 23229426 — intervention group
Group type: COMPARATOR
Intervention: Regular drain without suction (Control Group B)
Number of subjects: 151
Study 19231042 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with galacto- and fructo-oligosaccharides
Number of subjects: 342
Study 19231042 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 342
Study 17472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan 100 mg or 300 mg daily
Number of subjects: 42
Study 17472992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 17472992 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitaxsentan (in blinded extension study)
Number of subjects: 42
Study 15306858 — intervention group
Group type: EXPERIMENTAL
Intervention: Open mesh repair
Number of subjects: 40
Study 15306858 — intervention group
Group type: COMPARATOR
Intervention: Conventional (McVay) repair
Number of subjects: 40
Study 15306858 — intervention group
Group type: EXPERIMENTAL
Intervention: Sick leave of one to three weeks
Number of subjects: 40
Study 12112913 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 Fr IABC catheter
Number of subjects: 9332
Study 12112913 — intervention group
Group type: COMPARATOR
Intervention: 9.5 Fr IABC catheter
Number of subjects: 9332
Study 9615797 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte/macrophage colony stimulating factor (GM-CSF), administered as subcutaneous injections for 7 consecutive days to 14 patients.
Number of subjects: 29
Study 9615797 — intervention group
Group type: COMPARATOR
Intervention: Placebo, administered as subcutaneous injections for 7 consecutive days to 15 patients.
Number of subjects: 29
Study 7708896 — intervention group
Group type: EXPERIMENTAL
Intervention: Melodic contexts using pure-tone sequences generated from diatonic or nondiatonic tonesets with manipulated pitch-distributional information.
Number of subjects: 0
Study 7708896 — intervention group
Group type: EXPERIMENTAL
Intervention: Melodic contexts using pure-tone sequences with fixed temporal order of tones.
Number of subjects: 0
Study 7708896 — intervention group
Group type: EXPERIMENTAL
Intervention: Diatonic sequences for musically trained listeners.
Number of subjects: 0
Study 7708896 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal location of tones in sequences (randomized across trials) for musically untrained listeners in Experiment 3.
Number of subjects: 0
Study 2653015 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 40
Study 2653015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 98548 — intervention group
Group type: EXPERIMENTAL
Intervention: Early discharge (48 hours post-operation)
Number of subjects: 0
Study 98548 — intervention group
Group type: COMPARATOR
Intervention: Long stay (6 to 7 days post-operation)
Number of subjects: 0
Study 31533292 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise session (video demonstration via website), delivered twice a day for 12 consecutive weeks
Number of subjects: 282
Study 31533292 — intervention group
Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 282
Study 28877225 — intervention group
Group type: EXPERIMENTAL
Intervention: Active water-based recovery
Number of subjects: 17
Study 28877225 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive water-based recovery
Number of subjects: 17
Study 28877225 — intervention group
Group type: COMPARATOR
Intervention: Active land-based recovery
Number of subjects: 17
Study 28877225 — intervention group
Group type: COMPARATOR
Intervention: Passive land-based recovery
Number of subjects: 17
Study 26083769 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesotherapy with sodium diclofenac (25mg/1mL), 1mL for each session, three times per week for nine sessions.
Number of subjects: 117
Study 26083769 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of sodium diclofenac (50mg) once a day for 3 weeks.
Number of subjects: 117
Study 23895817 — intervention group
Group type: EXPERIMENTAL
Intervention: aVR ST-deviation (ST-depression 5%, ST-elevation 10.2%)
Number of subjects: 5683
Study 23895817 — intervention group
Group type: EXPERIMENTAL
Intervention: aVR ST-elevation
Number of subjects: 5683
Study 23895817 — intervention group
Group type: EXPERIMENTAL
Intervention: aVR ST-depression
Number of subjects: 5683
Study 21889083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed orthodontic appliances
Number of subjects: 20
Study 21889083 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated subjects)
Number of subjects: 20
Study 19660420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (0.01 microg x kg(‐1) x min(‐1) for 5 days)
Number of subjects: 94
Study 19660420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 94
Study 17311640 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2%
Number of subjects: 40
Study 17311640 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.125%
Number of subjects: 40
Study 15173400 — intervention group
Group type: EXPERIMENTAL
Intervention: Yeast-leavened oat bread with high molecular weight β-glucan (HMW) (797 kDa)
Number of subjects: 22
Study 15173400 — intervention group
Group type: COMPARATOR
Intervention: Yeast-leavened oat bread with low molecular weight β-glucan (LMW) (217 kDa)
Number of subjects: 22
Study 11386413 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) chemotherapy
Number of subjects: 47
Study 11386413 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose (SD) chemotherapy
Number of subjects: 47
Study 11386413 — intervention group
Group type: COMPARATOR
Intervention: Control group (not treated with chemotherapy)
Number of subjects: 47
Study 9740230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus
Number of subjects: 26
Study 9740230 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% tacrolimus
Number of subjects: 26
Study 9740230 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone-valerate
Number of subjects: 26
Study 9740230 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 26
Study 8002509 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion (0.5 g/min) after placebo (Pl)
Number of subjects: 8
Study 3201128 — intervention group
Group type: EXPERIMENTAL
Intervention: FF5005 (pectin-containing formulation)
Number of subjects: 6
Study 3201128 — intervention group
Group type: COMPARATOR
Intervention: Test meal (radiolabelled with technetium-99m)
Number of subjects: 6
Study 3201128 — intervention group
Group type: EXPERIMENTAL
Intervention: FF5005
Number of subjects: 6
Study 31391479 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine
Number of subjects: 27
Study 31391479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 28199216 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 30
Study 28199216 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 30
Study 25932839 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration
Number of subjects: 500
Study 25932839 — intervention group
Group type: COMPARATOR
Intervention: Electric vacuum aspiration
Number of subjects: 500
Study 25932839 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual vacuum aspiration (in pregnancies of sac size 3 mm or less)
Number of subjects: 500
Study 25932839 — intervention group
Group type: COMPARATOR
Intervention: Electric vacuum aspiration (in pregnancies of sac size 3 mm or less)
Number of subjects: 500
Study 25932839 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 500
Study 24143900 — intervention group
Group type: COMPARATOR
Intervention: IV
Number of subjects: 12
Study 24143900 — intervention group
Group type: COMPARATOR
Intervention: AL
Number of subjects: 12
Study 24143900 — intervention group
Group type: COMPARATOR
Intervention: IV + OR
Number of subjects: 12
Study 24143900 — intervention group
Group type: COMPARATOR
Intervention: NF
Number of subjects: 12
Study 24143900 — intervention group
Group type: COMPARATOR
Intervention: NF, AL, OR, IV
Number of subjects: 12
Study 21445574 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic lamivudine
Number of subjects: 42
Study 21445574 — intervention group
Group type: COMPARATOR
Intervention: Control (no prophylactic lamivudine)
Number of subjects: 42
Study 19721848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) in women with bulimia using serotonin reuptake inhibitors
Number of subjects: 64
Study 19721848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) in bulimic women not using medications
Number of subjects: 64
Study 19721848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD) in normal-eater control women
Number of subjects: 64
Study 19721848 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal-eater women)
Number of subjects: 64
Study 17192328 — intervention group
Group type: EXPERIMENTAL
Intervention: orlistat 120 mg t.i.d.
Number of subjects: 383
Study 17192328 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 383
Study 15339330 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment (administered intravenously three times)
Number of subjects: 42
Study 15339330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 15339330 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment (once)
Number of subjects: 42
Study 15339330 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab treatment
Number of subjects: 42
Study 12221344 — intervention group
Group type: EXPERIMENTAL
Intervention: Manipulative therapy
Number of subjects: 200
Study 12221344 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 200
Study 12221344 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 200
Study 12221344 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment in Northern California (NoCal)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in Northern California (NoCal)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet treatment in New England (NewEng)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in New England (NewEng)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal blood glucose testing in Southern California (SoCal)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose testing in Southern California (SoCal)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal blood glucose group in Southern California (SoCal)
Number of subjects: 3
Study 9704239 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial blood glucose group in Southern California (SoCal)
Number of subjects: 3
Study 9704239 — intervention group
Group type: COMPARATOR
Intervention: Postprandial monitoring in Southern California (SoCal)
Number of subjects: 3
Study 8032580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadralazine 10 mg once daily
Number of subjects: 14
Study 8032580 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone 25 mg once daily
Number of subjects: 14
Study 8032580 — intervention group
Group type: COMPARATOR
Intervention: Both cadralazine and chlorthalidone
Number of subjects: 14
Study 2681087 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral prophylaxis with cefazolin 1 g every 6 hours for 24 hours (2 g for knee-replacement)
Number of subjects: 105
Study 2681087 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of bone cement impregnated with antibiotics (e.g. Palacos-Gentamycin-cement)
Number of subjects: 105
Study 2681087 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation performed in a theater with 'ultra-clean-air' laminar air-flow and use of 'whole-body-exhaust' suits
Number of subjects: 105
Study 2681087 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic selection adjusted based on ongoing monitoring of antimicrobial resistance
Number of subjects: 105
Study 8187 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 8187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 8187 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 0
Study 31676174 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap balance technique
Number of subjects: 50
Study 31676174 — intervention group
Group type: COMPARATOR
Intervention: Measured resection technique
Number of subjects: 50
Study 30374683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg CBD twice daily
Number of subjects: 42
Study 30374683 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg CBD twice daily
Number of subjects: 42
Study 30374683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg CBD single dose
Number of subjects: 42
Study 30374683 — intervention group
Group type: COMPARATOR
Intervention: Single ascending doses (1500, 3000, 4500 or 6000 mg CBD)
Number of subjects: 42
Study 30374683 — intervention group
Group type: COMPARATOR
Intervention: Multiple dose (750 or 1500 mg CBD)
Number of subjects: 42
Study 30374683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 27382815 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M: 15 ml of bupivacaine 0.5% + 1 ml of 50 mg MgSO4
Number of subjects: 40
Study 27382815 — intervention group
Group type: COMPARATOR
Intervention: Group C: 15 ml of bupivacaine 0.5% + 1 ml of normal saline
Number of subjects: 40
Study 27382815 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M and Group C
Number of subjects: 40
Study 25699352 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water infusion
Number of subjects: 122
Study 25699352 — intervention group
Group type: COMPARATOR
Intervention: Standard air insufflation
Number of subjects: 122
Study 23087776 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic massage (TM)
Number of subjects: 35
Study 23087776 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 35
Study 21224783 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates exercises
Number of subjects: 52
Study 21224783 — intervention group
Group type: COMPARATOR
Intervention: Home exercises
Number of subjects: 52
Study 18052699 — intervention group
Group type: EXPERIMENTAL
Intervention: Anorganic bovine-derived hydroxyapatite matrix/cell-binding peptide (P-15)
Number of subjects: 12
Study 18052699 — intervention group
Group type: COMPARATOR
Intervention: Open flap debridement (OFD)
Number of subjects: 12
Study 18052699 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 12
Study 16356805 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 4162
Study 16356805 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 4162
Study 12121424 — intervention group
Group type: EXPERIMENTAL
Intervention: Brace with early range of motion (ROM) exercises from postoperative day 7
Number of subjects: 50
Study 12121424 — intervention group
Group type: COMPARATOR
Intervention: Plaster immobilization with ROM exercises starting 4 weeks postoperatively
Number of subjects: 50
Study 12121424 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study 10402814 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol titration using BIS maintained at 40 during induction (n = 15)
Number of subjects: 30
Study 10402814 — intervention group
Group type: COMPARATOR
Intervention: Bolus infusion of propofol 2 mg.kg‐1 (n = 15)
Number of subjects: 30
Study 10402814 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (titration and bolus)
Number of subjects: 30
Study 7538179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment using imipenem/cilastatin sodium (IPM/CS) with G-CSF
Number of subjects: 30
Study 7538179 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy on antibiotic
Number of subjects: 30
Study 7538179 — intervention group
Group type: COMPARATOR
Intervention: IPM/CS in combination with other antibiotics
Number of subjects: 30
Study 2248066 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 47
Study 2248066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 7303774 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term lithium therapy (7 days) in combination with methimazole
Number of subjects: 0
Study 7303774 — intervention group
Group type: COMPARATOR
Intervention: Methimazole monotherapy
Number of subjects: 0
Study 31615388 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine
Number of subjects: 0
Study 31615388 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of β‐AB and Ivabradine
Number of subjects: 0
Study 28728604 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT (clinical prediction tool) with matched treatment recommendation
Number of subjects: 1320
Study 28728604 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus Target-D attention control
Number of subjects: 1320
Study 28728604 — intervention group
Group type: EXPERIMENTAL
Intervention: CPT (clinical prediction tool)
Number of subjects: 1320
Study 26346932 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention including leadership commitment, surveillance of materials, reminders, storyboard, and feedback.
Number of subjects: 705
Study 26346932 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 705